Chronic Liver Diseases Therapeutics Global Market Report 2025

The chronic liver disease therapeutics market size has grown rapidly in recent years. It will grow from $14.38 billion in 2024 to $15.92 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth observed during the historical period can be attributed to a rise in the incidence of viral hepatitis, increasing obesity rates, an aging population, enhanced awareness of liver health, and improved patient access to treatment.

The chronic liver disease therapeutics market size is expected to see rapid growth in the next few years. It will grow to $23.83 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The projected growth in the forecast period can be attributed to an increased focus on personalized medicine, a burgeoning pipeline of novel therapies, the expansion of telemedicine and digital health solutions, a rising demand for liver disease prevention programs, and the increasing incidence of viral hepatitis. Major trends include the integration of artificial intelligence in diagnostics, the development of biologics and gene therapies, the emergence of non-invasive treatment options, the adoption of combination therapies, and the expansion of patient-centric care models.

The rising consumption of alcohol is expected to drive the growth of the chronic liver disease therapeutics market. Alcohol consumption refers to the intake of ethanol-containing beverages, ranging from moderate to excessive use, which can impact health. The increase in alcohol consumption is attributed to growing social acceptance, higher incomes, and greater accessibility worldwide. Chronic liver disease therapeutics play a crucial role in managing liver damage caused by excessive alcohol intake, slowing disease progression, and enhancing liver function. For example, in June 2024, First Citizens Bank, a US financial institution, reported a 1.2% rise in direct-to-consumer (DTC) wine case sales in 2023 compared to 2022. Additionally, in December 2023, a report published by Kirin Holdings Company Limited, a Japan-based beverage company, indicated that approximately 192.1 million kiloliters of beer were consumed in 2022, marking a 2.9% increase from the previous year. As a result, the rising consumption of alcohol is contributing to the expansion of the chronic liver disease therapeutics market.

Leading companies in the chronic liver disease therapeutics sector are prioritizing the development of advanced innovations, such as RNA therapies, to address genetic and molecular mechanisms, providing more targeted and effective treatment options. RNA therapies are cutting-edge medical treatments that utilize RNA molecules to regulate gene expression or protein production, with the aim of treating or preventing diseases by targeting specific genetic mechanisms. For instance, in May 2022, Ochre Bio, a UK-based biotech company, introduced its ‘Liver ICU’ research facility at BioLabs@NYULangone, a biopharma incubator in New York City. This advanced facility evaluates the efficacy of next-generation RNA therapeutics using whole human livers maintained on perfusion machines. By utilizing discarded donor livers for research, the facility seeks to accelerate drug development and enhance the accuracy of liver treatment studies by replicating human physiological conditions.

In March 2024, Gilead Sciences Inc., a US-based pharmaceutical company, completed the acquisition of CymaBay Therapeutics Inc. for approximately $4.3 billion. This acquisition is intended to strengthen Gilead Sciences’ portfolio in liver disease treatments, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other chronic liver conditions. CymaBay Therapeutics Inc. is a US-based company dedicated to developing therapies for liver diseases, including chronic liver conditions.

Major players in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy's Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.

North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in chronic liver diseases therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic liver disease therapeutics encompasses the treatments and interventions designed to manage long-term liver conditions. These therapies aim to slow disease progression, alleviate symptoms, and enhance liver function through the use of medications, lifestyle modifications, and, in some cases, advanced procedures.

The primary treatment types in chronic liver disease therapeutics include antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapies, and chemotherapy. Antiviral drugs are specifically formulated to inhibit the replication of viruses in the body, aiding in the treatment and management of viral infections. These therapies address a range of conditions such as hepatitis, autoimmune diseases, non-alcoholic fatty liver disease, cancer, and genetic disorders. Distribution channels for these treatments include hospital pharmacies, retail pharmacies, and online pharmacies.

The chronic liver diseases therapeutics market research report is one of a series of new reports that provides chronic liver diseases therapeutics market statistics, including the chronic liver diseases therapeutics industry global market size, regional shares, competitors with the chronic liver diseases therapeutics market share, detailed chronic liver diseases therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic liver diseases therapeutics industry. This chronic liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic liver disease therapeutics market includes revenues earned by entities by providing services such as genetic and molecular testing, liver transplantation, enzyme inhibitors, regular monitoring, and palliative and symptomatic care and related products, including pharmacological treatments, drugs, and emerging therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.